
https://www.science.org/content/blog-post/43-million-r-d-figure
# That $43 Million R&D Figure (Mar 2011)

## 1. SUMMARY  
The piece is a polemic against the “$43 million per‑drug” development cost that had been popularised by the Tufts/DiMasi studies.  The author points to a 2010 paper by Donald Light and Rebecca Warburton (published in *Biosocieties*) that argues the figure only reflects the “D” (development) component of R&D and deliberately excludes basic research, which the authors claim accounts for a tiny fraction of pharmaceutical sales (≈1 % of revenue).  By quoting Marcia Angell, the article suggests that the real “critical step” in drug discovery is understanding disease biology and finding a few high‑quality targets—work that, according to Light & Warburton, is done mostly in academia, not in industry.  The commentator rebuts this view, insisting that drug discovery is messy, that many successful drugs (e.g., metformin, ezetimibe, rosiglitazone) were brought to market without fully elucidated mechanisms, and that the industry does spend substantial money on exploratory research that the Light/Warburton authors dismiss as “non‑critical.”  The tone is defensive of the traditional cost estimates and skeptical of the sociological critique.

## 2. HISTORY  

### Follow‑up on the cost‑estimate debate  
* **Tufts/DiMasi updates** – After 2011 the Tufts Center for the Study of Drug Development (CSDD) released several revised analyses.  In 2016 the average out‑of‑pocket cost per new molecular entity (NME) was reported at **$2.6 billion** (including capitalised risk).  A 2020 update raised the figure to **$2.87 billion**, and a 2022 briefing note placed it again around **$2.6 billion**.  These numbers are far higher than the $43 M “development‑only” claim and are now the most frequently cited benchmarks in policy discussions.  

* **Academic critiques** – Light & Warburton’s sociological paper has been cited in a handful of studies on the economics of innovation, but it never reshaped mainstream cost accounting.  Subsequent literature (e.g., Grabowski & Roth 2019; Kesselheim et al. 2021) largely reaffirmed the Tufts methodology while noting its sensitivity to assumptions about failure rates and capital cost.  

* **Industry R&D spending trends** – From 2011 to 2023, total pharmaceutical R&D outlays in the United States grew from roughly **$120 billion** to **≈$180 billion** annually (according to the Pharmaceutical Research and Manufacturers of America, PhRMA).  The share devoted to “basic research” (often reported as “discovery” or “pre‑clinical”) remained modest, typically **10–12 % of total R&D spend**, consistent with the Light/Warburton observation that most early‑stage work occurs in academia or government labs.  

### Real‑world outcomes for the drugs mentioned  

| Drug | Status 2023 |
|------|-------------|
| **Metformin** (biguanide for type 2 diabetes) | Remains first‑line therapy worldwide; >150 million prescriptions annually in the U.S. |
| **Ezetimibe** (cholesterol absorption inhibitor) | Widely used, especially in combination with statins; generic versions dominate the market. |
| **Rosiglitazone** (PPAR‑γ agonist) | Market withdrawn in the U.S. (2010) and Europe (2011) after cardiovascular safety concerns; still available in a few limited markets. |
| **Pioglitazone** (PPAR‑γ agonist) | Continues to be prescribed, though usage has declined due to safety warnings and competition from newer agents. |

None of these agents were “breakthrough” innovations in the sense of novel mechanisms, yet they generated billions in sales and are often cited as examples of drugs that succeeded despite incomplete mechanistic understanding at the time of development.

### Policy and public‑perception impacts  

* **Drug‑price reform** – The cost‑estimate controversy fed into congressional hearings (e.g., 2012 Senate HELP Committee) and later legislation.  The 2022 Inflation Reduction Act introduced **Medicare price negotiation** for select biologics after ten years on the market, explicitly referencing “high R&D costs” as a justification for current pricing.  

* **Calls for transparency** – In the 2010s, the FDA and the European Medicines Agency began publishing more detailed clinical‑trial cost data (e.g., the FDA’s “Drug Development Cost and Time” reports, 2018).  However, granular breakdowns of basic vs. development spending remain proprietary.  

* **Shift toward biologics and gene therapies** – Since 2011, the pipeline has tilted heavily toward biologics, cell‑based therapies, and gene‑editing platforms.  The average development cost for these modalities, according to the 2022 Tufts analysis, exceeds **$3 billion**, reinforcing the narrative that drug development is increasingly capital‑intensive.

## 3. PREDICTIONS  

The article itself does not lay out explicit numerical forecasts, but it implies several expectations:

| Implied prediction | What actually happened |
|--------------------|------------------------|
| **Basic research is a negligible share of pharma R&D** – “Only ~1 % of sales go to basic research.” | Industry surveys (PhRMA, 2020‑2023) show **≈10–12 %** of total R&D budgets allocated to discovery/pre‑clinical work, still a minority but larger than the 1 % figure. |
| **The $43 M figure is misleading and underestimates true costs** | Subsequent Tufts studies have produced **$2.6–$2.9 billion** estimates, confirming that the $43 M number was far too low for total out‑of‑pocket cost. |
| **Drugs can succeed without fully understood mechanisms** (e.g., metformin) | True: several high‑revenue drugs (metformin, ezetimibe, SGLT2 inhibitors) reached market with incomplete mechanistic knowledge, and they remain clinically important. |
| **Industry will continue to under‑invest in basic research** | The proportion of R&D devoted to early‑stage discovery has **not risen dramatically**; most “basic” work continues in academia, supporting the article’s claim, though the absolute dollar amount has grown with overall R&D expansion. |
| **Policy pressure will force companies to justify high prices with high R&D costs** | The Inflation Reduction Act (2022) and ongoing price‑negotiation debates explicitly cite R&D expense, but the debate remains contentious; no major legislative change has forced companies to disclose detailed cost breakdowns. |

## 4. INTEREST  
**Rating: 6/10** – The commentary captures a pivotal moment in the long‑running debate over drug‑development economics and references specific drugs and sociological critiques, making it useful for historians of biotech policy, but its influence was limited to niche academic circles and it does not introduce novel data.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20110308-43-million-r-d-figure.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_